Skip to main content

Table 5 Association between hormone levels and the MMSE and EPIC scores: multivariate analysis

From: Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels

MMSE

     

 6Mo hormone levels

 

B

Odds ratio

95% CI

p

 

E2

-1.47

0.23

0.073-0.724

0.012

 

A-dione

0.021

1.02

1.006-1.036

0.006

 

cortisol

-0.059

0.94

0.898-0.989

0.016

EPIC

     

 Hormone levels and QOL at each observation point

     

 PRE

     

  Sexual bother

A-dione

-0.02

0.98

0.964-0.997

0.019

 6Mo

     

  Sexual bother

E2

1.57

4.81

1.086-21.33

0.039

 

T

-61.15

2.76 × 10-27

1.34 × 10-5-0.00057

0.026

 

DHT

0.21

1.017

1.028-1.484

0.024

  Hormonal function

E2

1.14

3.12

1.13-8.64

0.028

 

A-dione

-0.019

0.98

0.97-0.998

0.026

  Hormonal bother

E2

2.006

7.44

1.82-30.30

0.005

 

T

-30.8

4.19 × 10-14

4.32 × 10-24-0.00041

0.017

 

cortisol

0.076

1.08

1.02-1.14

0.008

 12Mo

     

  Sexual bother

E2

1.082

2.95

1.11-7.82

0.030

  Hormonal bother

A-dione

-0.0089

0.991

0.983-0.9997

0.042

 

DHEA-S

-0.0174

0.983

0.966-0.999

0.049

  1. B: regression coefficient.
  2. PRE: pretreatment 6MO: 6 months after initiation of LH-RH agonist treatment.
  3. 12MO: 12 months after initiation of LH-RH agonist treatment.
  4. T: testosterone, DHT: dihydrotestosterone, E2; estradiol, DHEA-S: dehydroepiandrosterone-sulfate.
  5. A-dione: androstenedion, MMSE: mini-mental state examination.
  6. EPIC: expanded postate cancer index composite.